1
|
Rivosecchi RM, Kellum JA, Dasta JF, Armahizer MJ, Bolesta S, Buckley MS, Dzierba AL, Frazee EN, Johnson HJ, Kim C, Murugan R, Smithburger PL, Wong A, Kane Gill SL. Drug Class Combination–Associated Acute Kidney Injury. Ann Pharmacother 2016; 50:953-972. [DOI: 10.1177/1060028016657839] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Objective: To evaluate the quality of available evidence of drug class combinations and their association with the development of acute kidney injury (AKI). Data Sources: A search of MEDLINE and Embase databases was completed using the following terms: “risk factor AND (acute kidney injury or acute kidney failure) AND (drug or medication).” Study Selection and Data Extraction: Inclusion criteria were the following: English language, full-text availability, and at least 1 drug-combination. Each citation was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) criteria. The literature was evaluated using the quality of evidence component of GRADE. No standardized definition of AKI was applied throughout.. Data Synthesis: Out of 2139 total citations, 151 were assessed for full-text review, with 121 citations (6%) meeting inclusion criteria, producing76 unique drug class combinations. Overall, 56 combinations (73.7%) were considered very low quality; 12 (15.8%) were considered low quality. There were 8 (10.5%) of moderate quality, and no combination was considered high quality. 58 (76%) combinations that had a single citation,with a mean of 1.6 citations per drug class combination. The combination of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics was reported in 10 citations, the largest number of citations. Conclusions: Our study demonstrates a lack of well-designed studies addressing drug class combination–associated AKI. The combination of NSAIDs and diuretics with or without additional renin-angiotensin aldosterone agents had the strongest level of evidence. Despite limitations, the information included in this review may result in additional scrutiny about combining certain individual nephrotoxic drugs.
Collapse
Affiliation(s)
| | | | | | | | - Scott Bolesta
- Wilkes University Nesbitt College of Pharmacy, PA, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Brückner O, Kroening U, Nagel R. [Tobramycin concentrations in human renal tissue (author's transl)]. Infection 1979; 7:283-9. [PMID: 397936 DOI: 10.1007/bf01642150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Investigation of kidneys from 20 patients revealed relatively low tobramycin concentrations in cortex and medulla after one day of treatment. After administration for several days a significant accumulation was observed in only one of three patients. Attention is drawn to the higher tobramycin concentrations found in renal parenchyma which has undergone chronic inflammatory changes compared to the "normal" values in kidneys infiltrated by tumours. A higher accumulation thus occurs in renal tissue which has already undergone structural damage as a result of bacterial inflammation.
Collapse
|